Kornimate/medical-research-clean huggingface dataset:
hepatitis b research network adult cohort study

Conditions: Hepatitis B

Summary: the primary purpose of this study is to describe participants with hepatitis b virus (hbv) infection and identify factors that may cause the disease to activate or worsen.

aims * primary aim: o to describe participants with hepatitis b virus (hbv) infection in a prospective cohort in the united states (us) and canada and identify predictors of disease activation and progression * secondary aims: * to describe clinical, virological, and immunological characteristics of participants with hbv in the us and canada * to evaluate changes in hbv infection status and quantitative hepatitis b surface antigen (hbsag) levels and factors associated with those changes * to verify whether a baseline hbsag below 1,000 iu/ml and hbv dna below 1,000 iu/ml is an accurate predictor of people who are, or who will become, inactive carriers, defined as people who are hbsag positive, hepatitis b "e" antigen (hbeag) negative, have normal alanine transaminase (alt) and hbv dna under 1,000 iu/ml on at least two occasions over a period of at least 6 months * to develop a bank of biospecimens (e.g., serum, plasma, dna, lymphocytes, liver tissue) obtained from participants with hbv infection * to identify participants with hbv infection who are potential candidates in one of the treatment studies to be conducted by the hepatitis b research network (hbrn) * to describe the natural history of hepatitis b infection in pregnancy including the frequency of, and clinical and virological characteristics associated with, hepatic flares during pregnancy and post-partum.

Eligibility criteria:
the study population will be recruited from multi-site clinical centers in the united states and canada including primary care hospitals and community centers. inclusion criteria * written informed consent * at least 18 years of age * hepatitis b surface antigen (hbsag) positive and either: * pregnant * anti-hepatitis d positive * diagnosed with acute hepatitis b infection or experiencing a hepatitis flare * immune tolerant or immune active phenotype * potentially eligible for the immune regulation and costimulation in natural history of chronic hepatitis b ancillary study (nct01298037). exclusion criteria: * hepatic decompensation * hepatocellular carcinoma (hcc) * liver transplantation * current hepatitis b antiviral treatment (except pregnant women and patients who are anti-hdv positive) * known human immunodeficiency virus (hiv) co-infection (patients with hepatitis d (hdv) or hepatitis c (hcv) co-infection are not excluded). * medical or social condition which in the opinion of the investigator will interfere with or prevent follow-up per protocol * unable or unwilling to return for follow-up visits

Keywords: hepatitis b hbv cohort study
prostate impendance test project

Conditions: Prostatic Neoplasms; PSA; Prostatic Biopsy; Impedance Test

Summary: impedance-based analysis could provide an adequate response to the need to identify a safe and reliable tool alternative to bioptic diagnosis. patients who are candidates for prostate biopsy as suffering from urinary symptoms accompanied by clinical suspicions such as high total psa value and / or presence of prostate nodule and / or evidence of obvious lesion to available imaging methods will be subjected to impedance measurement. aim of this study is to be able to structure a bivariate analysis of the distribution of impedances detected in patients with neoplasia in order to detect test median reference values.


Eligibility criteria:
inclusion criteria: 1. age\> 45 years 2. up of total psa values beyond the normal range (\> 4 ng / ml) 3. presence or absence of suspicious prostate nodule exclusion criteria: 1. previous history of cancer 2. bmi\>30 3. patients with previous diagnosis of pin hg at prostate core biopsy or in active surveillance
study of car-t cell therapy in the treatment of relapsed/refractory hematological malignancies

Conditions: Relapsed/Refractory Hematological Malignancies; Lymphoma; Myeloma; Leukemia

Summary: the primary purpose of this study is to determine the safety and efficacy of novel autologous car-t cells in patients with relapsed/refractory hematological malignancies.

car-t cells targeted cd19 have demonstrated unprecedented successes. besides cd19, many other molecules such as cd123, bcma, and cd7 may be potential in developing the corresponding car-t cells to treat patients with hematopoietic and lymphoid malignancies. utc therapeutics inc. have developed an efficient platform for constructing car-t cells that can remodel of tumor microenvironment and enhance the anti-tumor immune response and persistence of car-t cells. in this study, all eligible subjects will receive a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by investigational treatment, car-t cells. safety and efficacy of the car-t cells will be assessed.

Eligibility criteria:
inclusion criteria: 1. histological diagnosis of hematological malignancies (such as lymphoma, myeloma, leukemia) refractory to, or relapsing after standard therapy. 2. positive expression of specific antigens. 3. eastern cooperative oncology group (ecog) performance status of 0\~2. 4. adequate organ functions: * serum bilirubin ≤ 35 μmol/l; * serum aspartate aminotransferase (ast)/alanine aminotransferase (alt) \< 2; * serum creatinine (cr) ≤ 2 × upper limit of normal (uln); * brain natriuretic peptide (bnp)\<80 pg/ml. 5. subjects must be able to understand the protocol and be willing to enroll the study, sign the informed consent, and be able to comply with the study and follow-up procedures. exclusion criteria: 1. history of allergy to any of the drugs involved in the protocol. 2. history of cardiac diseases: * left ventricular ejection fraction (lvef) \< 50%; * class iii or iv heart failure as defined by the new york heart association (nyha). 3. history of another malignancy tumor. 4. active hepatitis c (hcv), hepatitis b (hbv), human immunodeficiency virus (hiv), or syphilis infection. 5. patients with any contraindications to allogeneic hematopoietic stem cell transplantation. 6. uncontrolled fungal, bacterial, viral, or other infection. 7. female subjects who are pregnant or lactating.

Keywords: cd19 car-t bcma car-t cd7 car-t cd123 car-t
bilateral ultrasound-guided intra muscular quadratus lumborum block versus trans muscular quadratus lumborum block for peri-operative analgesia in abdominal surgeries in pediatric patients. a comparative controlled randomized study.

Conditions: Pain, Acute

Summary: to compare between the intra muscular quadratous lamborum and the trans muscular quadratous lamborum in pediatric population under going abdominal surgeries regards to first request of rescue analgesia, degree of pain relief, effect on hemo dynamic stability and incidence of complications.

the investigators hypothesized that an ultrasound guided quadratous lamborum block would prove successful peri-operative analgesia for abdominal surgeries in pediatric patients, and that intra muscular quadratous lamborum is non inferior to trans muscular blockade with the advantage of being safer (away from the peritoneum and retroperitoneal organs) and with the assumption that sarcolemmal layer in pediatrics should not resist the diffusion of the injectant from within the muscle out, to reach the inter fascial plane where the targeted nerves are found and cause an efficient blockade.

Eligibility criteria:
inclusion criteria: * children age starting from 5 to 12 years. * genders eligible for study: both sexes. * american society of anesthesia (asa) i-iii. * scheduled to undergo laparoscopy. exclusion criteria: * refusal of regional block or patients requiring emergency procedures. * known local anesthetics drug sensitivity * bleeding disorders with international normalised ratio (inr) \> 1.5 and/or platelets \< 100 000. * skin lesions or wounds at site of proposed needle insertion. * evidence of peritonitis or septicemia. * hepatic disease or enlargement.
beta blockade in critical injury

Conditions: Trauma

Summary: critically injured patients endure a period of hypermetabolism/catabolism after being resuscitated. the metabolic cost of this may be measured in loss of lean body mass, poor wound healing, susceptibility to infection and long hospital stays. while there have been some data to suggest that hypermetabolism can be ameliorated in burn patients by beta blockade, to our knowledge, a prospective trial in trauma patients has not yet been done. our hypothesis is that nonselective beta blockade will reduce catabolism, improve glucose control, blunt loss of lean body mass, decrease infections and improve outcome in a cohort of critically injured patients.


Eligibility criteria:
inclusion criteria: * iss\>25, stable at 48 hours after injury * fully resuscitated * ventilated exclusion criteria include: * intracranial hypertension requiring active treatment * hypotension/pressors * already on beta blocker for a standard indication
prevalence of dental caries in a group of egyptian children

Conditions: Prevalence of Dental Caries and Its Relation to Screen Time and Sugar Consumption; Prevalence,Patient

Summary: prevalence of dental caries in a group of egyptian children and its relation to tv and other screens time and sugar consumption (observational cross-sectional study)

dental caries, are considered by the world health organization as a major public health problem globally, and the most widespread non-communicable disease. similar with other conditions that are described as non-communicable diseases (ncds), dental caries develops as the result of a combination of genetic, physiological, environmental and behavioral factors. the commonly accepted risk factors for dental caries include dietary habits (e.g., sugary snacks), poor oral hygiene, microbiological factors, and low socioeconomic status. watching tv during mealtime has a negative impact on children's dietary quality as it is associated with higher consumption of ultraprocessed foods . it was found that having the tv on at mealtimes reduces diet quality with more high-fat, high-sugar foods and fewer fruits and vegetables and increased consumption of sugar sweetened beverages. overconsumption of sugar has been associated with increased risk of excessive weight gain, dental decay, poor diet quality and nutritional inadequacy in children and adolescents younger than 19 years .

Eligibility criteria:
inclusion criteria: * 1. a child with mixed dentition aged from 6-8 years old 2. positive subject acceptance for participation in the study 3. access to all types of screens 4. both gender exclusion criteria: * 1. a child with a dental emergency 2. child with a psychological problem 3. child with chronic illness

Keywords: prevalence dental caries screen time sugar consumption
a phase 1b study assessing gs-7340 in treatment-naive adults with chronic hepatitis b

Conditions: Chronic Hepatitis B

Summary: this is an open-label study evaluating multiple doses of gs-7340 versus tenofovir disoproxil fumarate (tdf).

this is a randomized, open-label, active-controlled study whose primary objective is to evaluate the safety and efficacy of several doses of gs-7340. this study will evaluate the safety, viral kinetics, and antiviral activity of 4 different doses of gs-7340 over 28 days of therapy. in addition, the study will evaluate the antiviral activity of an optimal dose of gs-7340 versus 300mg tenofovir disoproxil fumarate (tdf) over 28 days of therapy.

Eligibility criteria:
inclusion criteria: * must be between 18 and 65 years of age * must have screening plasma hbv dna ≥ 2x10\^3 iu/ml * must have chronic hbv infection for at least 6 months * must have estimated creatinine clearance (clcr) ≥ 70 ml/min * not pregnant or nursing * women must be of non-childbearing potential or of childbearing potential with confirmed negative pregnancy tests * consistent and correct use of recommended methods of birth control for men and women exclusion criteria: * pregnant or lactating subjects * receipt of anti-hbv nucleoside/nucleotide therapy. subjects who have failed prior interferon treatment, greater than 6 months prior to screening, are permitted to participate in the study screening * known co-infection with hiv, hepatitis c virus (hcv) or hepatitis d virus (hdv) * presence of autoimmune disorders * history of liver disease other than hepatitis b * history of gilbert's disease * any sign of decompensated liver disease * known or suspected cirrhosis * evidence of hepatocellular carcinoma * presence or history of cardiovascular disease, cardiomyopathy, and/or cardiac conduction abnormalities * electrolyte abnormalities * history of treatment that permanently alters the gastric condition * alcohol or substance abuse * history of bleeding diathesis * significant bone disease

Keywords: hepatitis b hbv gs-7340 tdf tenofovir disoproxil fumarate gilead viread
the effect of diflunisal on familial transthyretin amyloidosis

Conditions: Amyloidosis

Summary: an ongoing trial of diflunisal has been closed for enrollment, thus, patients suitable for the study can no longer participate or receive treatment by diflunisal; and patients, who have participated in the trial can not continue their treatment. the investigators want to continue to monitor the effect of the drug on transthyretin (ttr) amyloidosis in an open label observational study. primary endpoint will be a composite score of the manifestations of the disease (kumamoto scale) and secondary end points will be measurements of neurological impairment, heart involvement and nutritional status.

duration of treatment in this study is dependent of the results from the ongoing ind 68092-study, which are planned to be presented 2013.

Eligibility criteria:
inclusion criteria: * biopsy and genetically proven systemic transthyretin amyloidosis caused by a ttr gene mutation. the amyloid shall be proven to be of transthyretin type, and the fibril composition settled. * age ≥ 18 years. * negative pregnancy test and contraception for sexually active women of child bearing potential. exclusion criteria: * concomitant use of non-study non-steroidal anti-inflammatory drugs (nsaids) * heart failure with symptoms at daily activities (nyha class ≥iii) * renal insufficiency (creatinine clearance \< 30 ml calculated from the cockcroft-gault formula) * active non-haemorrhoidal bleeding within the last 18 month. * non-treated peptic ulcer disease. * anticoagulation therapy, low dose asa permitted. * non-steroidal or aspirin allergy/hypersensitivity * thrombocytopenia (\< 100,000 platelets/mm3) * inability or unwillingness of subject to give written informed consent * by the investigator regarded as unable to follow the study guidelines and scheduled controls.

Keywords: amyloidosis transthyretin neuropathies diflunisal familial
chronic shoulder pain treated by pressures with the thumbs on the trigger points

Conditions: Shoulder Pain

Summary: the purpose of this study is to find the efficacy of treating the trigger points located around the shoulder in patients suffering from chronic shoulder pain.

chronic shoulder pain is a common condition which should be treated by surgery only wen conservative approaches have been tried. in the present trial the authors intend to find the effectiveness of treating the triggers points located in muscles, ligaments and tendons surrounding the shoulderin patients suffering from chronic shoulder pain. the technique used in this trial is ischemic compression(thumb tip pressure) on the trigger points

Eligibility criteria:
inclusion criteria: * 30 to 60 years old. * to have suffered from shoulder pain on a daly basis for at least 3 months * participants had to be able to raise the arm above ther head. * they had accept to receive 15 chiropractic treatments without charge. exclusion criteria: * past surgery to the arm. * injection to the shoulder in the month preceding the trial. * a diagnosis of rheumatoid arthritis or any other systemic disorders affecting the joints. * shoulder pain from an herniated disc.

Keywords: chiropractic myofascial trigger points ischemic compression shoulder pain
affect of dose rate on uvr induced skin erythema

Conditions: Erythema

Summary: purpose of study: evaluation of the affect of dose rate on uvr induced skin erythema. study design: a single-center, prospective, randomized, crossover, open study. number of patients: 20-40 patient population: healthy volunteers control: different sites on patients body procedure duration: total 3-5 hours (4 visits) duration of follow up: 4 days duration of study: up to 6 months primary objectives: to examine the difference in erythemal response as a function of dose rate, and to assess the total amount of energy that is theoretically transmitted through a sunscreen within the range of spf 2-10.


Eligibility criteria:
inclusion criteria: * fitzpatrick skin types i-iii. * age 18-60. * absence of obvious sun damage on the volar side of the forearm or other exposure sites. * absence of exposure of the arms or other exposure sites to sunlight for two weeks prior to the experiment. exclusion criteria: * history of skin cancer. * multiple nevi or atypical nevi on the forearm. * signs of sun damage on the volar side of the forearm or other exposure sites. * mentally incompetent.

Keywords: uvb induced skin erythema
a gbt021601 adme microtracer study in healthy volunteers

Conditions: Sickle Cell Disease

Summary: an open-label study of gbt021601 in 8 to 10 healthy male or female participants to evaluate the absorption, distribution, metabolism, and excretion (adme) of gbt021601.

this is an open-label study administering gbt021601 as a single oral dose of 200 mg in healthy participants.

Eligibility criteria:
inclusion criteria: * body mass index (bmi): 18.0 to 27.0 kg/m2, inclusive, at screening. * body weight ≥ 50 kg at screening * females must be nonlactating and nonpregnant (as confirmed by a negative serum pregnancy test at screening and admission for all females), or of nonchildbearing potential (ie, either surgically sterilized or physiologically incapable of becoming pregnant, or at least 1 year postmenopausal \[defined as at least 12 months no menses, and confirmed by a follicle-stimulating hormone test, at screening\]). * creatinine clearance (glomerular filtration rate) as estimated by the chronic kidney disease epidemiology collaboration (ckd-epi) formula: ≥90 ml/min, at screening. exclusion criteria: * history or presence of conditions which, in the opinion of the investigator, are known to interfere with the adme of drugs, such as previous surgery on the gastrointestinal tract (including removal of parts of the stomach, bowel, liver, gall bladder, or pancreas). participants who have a history of appendectomy are eligible for enrollment. * history of chronic constipation, or recent complaints of an irregular defecation * significant and/or acute illness at screening or within 5 days prior to study drug administration that may impact safety assessments, in the opinion of the investigator. * known personal or family history of congenital long qt syndrome or known family history of sudden death. * participation in another adme study with a radiation burden \>0.1 msv in the period of 1 year prior to screening.
pack cross linking for infectious keratitis

Conditions: Infectoius Keratitis

Summary: the primary aim of this study is to investigate the efficiency of pack_ cxl in treatment of infectious keratitis and analyze postoperative outcomes.


Eligibility criteria:
inclusion criteria: * are age ≥18 years, fungal, bacterial or mixed infectious keratitis, ulcer ≤ 4 mm in diameter and showing a maximum depth of 350 μm (as assessed by either optical coherence tomography (oct)) exclusion criteria: * age ≤18 years, viral infectious keratitis, non-infectiouskeratitis, melting corneal ulcers with impending perforation, corneal thickness \< 400 μm (including the corneal epithelium) and systemic diseases or systemic surgery, single-eyed and immunosuppressed patients.
position change and back massage versus early ambulation on post transfemoral coronary angiography complications

Conditions: Catheter Complications; Ambulation Difficulty; Bleeding; Back Pain; Oozing; Hematoma

Summary: the study aimed to assess the effect of position change and back massage versus early ambulation on post transfemoral coronary angiography complications.

post transfemoral coronary angiography (tfca) may be associated with complications such as oozing, bleeding, ecchymosis, hematoma, and back pain. as a result, nursing practice must be geared toward enhancing patient safety post-transfemoral coronary angiography procedure. this study aimed to assess the effect of position change and back massage versus early ambulation on post transfemoral coronary angiography complications. a quasi-experimental research design was used to conduct this study at the coronary care unit of the selected university hospital in egypt. a convenience sample of 185 patients undergoing transfemoral coronary angiography was included in the study during the first 6 hours post-transfemoral coronary angiography and randomly assigned to two groups: 92 patients received position change and back massage (pcbm group), and 93 patients underwent early ambulation after the first 3 hours post-transfemoral coronary angiography (ea group). the used tool was "post transfemoral coronary angiography complication assessment".

Eligibility criteria:
inclusion criteria: * mean arterial blood pressure ≥70 mmhg. * heart rate ≥ 60 b/m. * manual compression closure technique on the access site * partial thromboplastin time \< 90 seconds. * prothrombin time \<16 seconds). * no anticoagulant therapy within 24 hours before the cardiac catheterization procedure. exclusion criteria: * patients who had a history of previous coronary stents. * chronic pain, * chronic obstructive pulmonary disease. * renal failure, * hypercoagulable conditions such as protein c. * cardiopulmonary resuscitation during angiography. * femoral artery ruptures during angiography. * chest pain with new electrocardiograph change.

Keywords: coronary angiography complications early ambulation position transfemoral back massage